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Abstract
Background: Emerging reports propose possible biomarkers that are related to inflammation, nutrition and lipid
parameters for detection of the progression of atherosclerotic plaques, peripheral artery disease (PAD) and
particularly peripheral artery stenosis (PAS). However, it remains unclear which biomarkers in serum are associated
with the severity of PAS.
Findings: In this study, we measured serum levels of inflammatory biomarkers along with lipid and nutritional
parameters in 53 patients who suffered different degrees of PAS. Serum concentrations of vascular endothelial
growth factor-c (VEGF-C) and IL-6 (Interleukin 6) were significantly increased in patients showing moderate or
severe PAS. Furthermore, the number of blood monocytes from PAS patients was significantly increased, which
showed elevated adhesion to plate-coated fibrinogen. Compared to healthy subjects, freshly isolated or LPS
(lipopolysaccharide)-stimulated blood monocytes from PAS patients could produce VEGF-C and IL-6 at higher levels.
Conclusions: Our study suggests that the increased number of blood monocytes might play key roles during the
development of severe PAS, which enhance adhesion at the local narrowed peripheral artery and secret high levels
of VEGF-C and IL-6. We suggest that serum concentrations of VEGF-C and IL-6 might be used as biomarkers for
diagnosis severe PAS in combination with clinical imaging examination.
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Findings
Introduction
In patients with atherosclerotic peripheral artery stenosis
(PAS), the degree of stenosis and the structure of plaque are
important risk factors for cardiovascular events and adverse
limb events. Current optimal morphological evaluation of
PAS aims to make an accurate diagnosis through invasive
and non-invasive imaging techniques [1]. However, simple
methods, such as blood test of biomarkers, with potential
usage for high-throughput analysis and diagnosis of the se-
verity of PAS are not fully developed. Previous studies sup-
port that inflammation and innate immune cells including
monocytes or macrophages play important roles during the
development and progression of PAS [2, 3]. Various risk fac-
tors are used as potential criteria for detection of subclinical
PAS [2, 4–6], such as inflammatory biomarkers including C-
reactive protein (CRP), fibrinogen, lipoprotein, cholesterol,
along with blood glucose and triglyceride.
Recently, we reported that in response to bacterial in-
fection, macrophages increased the expression of soluble
vascular endothelial growth factor C (VEGF-C) and the
surface receptor VEGFR-3 (vascular endothelial growth
factor receptor-3, also termed Flt-4) in a Toll-like
receptor-4 (TLR4)-dependent manner. Further, serum
VEGF-C expression was substantially increased in sepsis
patients, suggesting serum VEGF-C as a new biomarker
for diagnosis of sepsis [7]. Previous findings have dem-
onstrated that upon binding to VEGF-C, the tyrosine
kinase receptor VEGFR-3 is activated [7–9]. Interest-
ingly, others also reported that VEGF-C is chemotactic
for recruitment of macrophages or T lymphocytes into
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target organs under pathological conditions [10, 11]. A
link has been established between pathogenesis of athero-
sclerosis and the VEGF family members, such as VEGF-A
(also termed VEGF) [12]. In addition, concentrations of
VEGF-A are enhanced and its binding to VEGFR-1 have
been linked with sepsis in humans and mice [13, 14]. Al-
though we provided evidence that serum VEGF-C levels
are associated with human or murine sepsis, it remains
unknown whether serum VEGF-C is linked to PAS sever-
ity. In this study, we examined the number of immune
cells and a series of inflammatory risk factors in blood
from moderate and severe PAS patients. We found that
serum VEGF-C and IL-6 concentrations were significantly
increased in severe PAS patients compared with healthy
subjects. Moreover, the number of blood monocytes in
PAS patients was increased with elevated adhesion to
plate-coated fibrinogen. Blood monocytes in PAS patients
also produced higher levels of VEGF-C and IL-6 (Interleu-
kin 6). It suggests that accumulation of adherent mono-
cytes at local narrowed peripheral artery might promote
production of inflammatory risk factors to increase the se-
verity of PAS.
Material and methods
Enroll of patients and healthy subjects
Multi-slice computed tomography (CT) was used to
analyze the grade of stenosis and morphology of soft or
hard plaque. According to the grade of stenosis and
plaque morphology, patients were divided into two
groups: Thirty-one patients with atherosclerotic periph-
eral artery stenosis >50 % but <80 %, twenty-two pa-
tients with stenosis ≥80 %. Twenty-seven healthy
subjects were enrolled. The exclusion criteria include a
recent infection, a recent acute coronary syndrome,
heart failure (NYHA class III of IV), stenosis with a
cause other than atherosclerosis, renal failure, and liver
disease. The levels of plasma triglycerides, HDL and
LDL cholesterol, fasting blood glucose, fibrinogen, and
white blood cell counts were determined by routine la-
boratory methods.
Preparation and immunostaining of PBMCs
Peripheral blood mononuclear cells (PBMCs) from
healthy people and PAS patients were isolated by density-
gradient centrifugation with Ficoll 1.077 (0850494, MP).
PBMCs were immunostained with anti-CD11b and anti-
F4/80 antibodies (11–0113 and 14–4801, eBioscience) in
PBS with 1 % BSA. Samples were analysed on a BD Accuri
C6 flow cytometry.
Monocytes isolation and LPS stimulation
Human monocytes were isolated from peripheral blood
using a modified Recalde method [15]. Briefly, 50 μL of
1.54 M NaCl was added into 10 mL PBS to suspend 3×107
PBMCs. After incubation at 37 °C for 10 min, an add-
itional 100 μL of 1.54 M NaCl was added, followed by a
third addition of 1.54 M NaCl (100 μL) 10 min later. Next,
the cells were diluted by the addition of 15 mL of hyper-
tonic PBS [1.54 M NaCl were added to PBS in a ratio of
1:36 (v/v)] and mixed by pipeting up and down. 10-mL ali-
quots were dispensed into 50-mL centrifuge tubes, and
mixed with an additional 15 mL of hypertonic PBS. Each
tube was then underlayered with 15 mL of hypertonic
Ficoll. Hypertonic Ficoll was prepared by adding 2.8 mg of
crystalline NaCl to each mL of Ficoll. The tubes were cen-
trifuged at 600 g for 15 min at 25 °C. The monocytes were
found at and below the interface in a broad band, which
was removed (approximately 15 ml). The contents of each
tube were diluted to 40 mL with PBS and centrifuged at
600 g for 15 min. The cell pellets were washed twice in
5 mM EDTA in PBS to remove platelets and resuspended
in DMEM. Then, monocytes were immunostained with
anti-CD14 antibody (557154, BD) and the average purity
was 70 % by FACS analysis. Monocytes were seeded into
96-well tissue culture plates at a density of 1.0×l05 per well
and stimulated with or without LPS (100 or 300 ng/mL)
for 24 h in DMEM.
Adhesion assay
A 24-well tissue culture plate was coated with fibrinogen
(F3879, Sigma) (10 μg/mL, dissolved in PBS) and incu-
bated at 4 °C overnight. PBMCs were seeded into the
plate at a density of 5×105 per well and cultured for 16 h
in DMEM without serum. After washed three times with
PBS, cells were stained with anti-CD11b antibody to
mark monocytes. Images were captured with Olympus
BX51 microscope and adherent monocytes were
counted.
Detection of cytokine concentrations
The concentrations of interleukin 6 (IL-6) and vascular
endothelial growth factor C (VEGF-C) in plasma and
supernatants were determined using ELISA kits
(BMS213INST & BMS297/2, eBioscience) according to
the manufacturer’s instructions.
RNA isolation and quantitative real-time reverse
transcriptase-polymerase chain reaction
Total RNA was isolated from PBMCs using TRIzol Re-
agent (DP405, TIANGEN), then converted to cDNA
using M-MLV reverse transcriptase (2641A, TAKARA).
Quantitative reverse transcriptase-polymerase chain re-
action (qRT-PCR) was performed on a CFX-96 machine
(Bio-rad) using SYBR Green master mix (DBI Bio-
science). Values were normalized for β-actin mRNA
levels. The average mRNA levels of IL-6, IL-1β and
VEGF-C in PBMCs from healthy subjects were set as
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1.00 and those from PAS patients were calculated as the
fold change.
Statistical analysis
Data are presented as mean ± SD. A two-tailed Student’s
t-test was used to compare two groups. ANOVA and
Dunnett’s test were used to analyze difference among
three groups. For all test, a P value of 0.05 or less was
considered statistically significant.
Results
PAS patients enhance the number of blood monocytes
and serum concentrations of IL-6 or VEGF-C
Multi-slice computed tomography (CT) was used to
analyze the grades of stenosis and morphology of soft or
hard plaque of patients. According to the grades of sten-
osis and morphology of plaque, patients were classified
into two groups and compared with age-matched
healthy subjects. Patients with atherosclerotic PAS 50 %
~ 80 % were defined as moderate PAS patients, and pa-
tients with PAS ≥80 % were defined as severe PAS
(Fig. 1a, the boxed area represents a typical narrowed ar-
tery). Compared with healthy subjects, the number of
leukocytes in blood was significantly increased in moder-
ate or severe PAS patients (Fig. 1b, left panel, healthy vs.
moderate PAS, P = 0.0072; healthy vs. severe PAS, P =
0.0004). Particularly, the number of monocytes in blood
from moderate or severe PAS patients was higher than
that of healthy subjects, (Fig. 1b, middle panel, healthy
vs. moderate PAS, P = 0.0174; healthy vs. severe PAS, P
= 0.0014). In contrast, both moderate and severe PAS
patients had the comparable number of lymphocytes in
blood compared with healthy subjects (Fig. 1b, right
panel).
We next examined which risk factors might show as-
sociation with the grades of PAS. Serum concentrations
of IL-6, VEGF-C, cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL), very low density
lipoprotein (VLDL), blood glucose and triglyceride from
PAS patients and healthy subjects were tested. Interest-
ingly, IL-6 and VEGF-C concentrations were substan-
tially increased in severe PAS patients compared with
those of healthy subjects (Fig. 1c, left panel, healthy vs.
severe PAS, P < 0.0001; right panel, healthy vs. severe
PAS, P < 0.0001). The levels of IL-6 were also signifi-
cantly increased in moderate PAS patients compared
with those of healthy subjects (Fig. 1c, left panel,
healthy vs. moderate PAS, P < 0.0001). Of note, moder-
ate PAS patients displayed similar levels of blood glu-
cose, triglyceride, HDL, LDL, VLDL, and cholesterol
compared with those of healthy subjects (Additional file
1: Figure S1A, B, C and D). Moreover, severe PAS pa-
tients had normal levels of blood glucose, triglyceride,
HDL and VLDL compared with those of healthy
subjects (Additional file 1: Figure S1A, B, C and D).
These data indicate that the elevated number of mono-
cytes, serum levels of IL-6 and VEGF-C are associated
with severe PAS.
Blood monocytes in PAS patients produce higher levels
of IL-6 and VEGF-C
To evaluate the role of monocytes in secretion of inflam-
matory cytokines, PBMCs in peripheral blood were pre-
pared from 8 healthy subjects and 9 PAS patients and
the percentage of monocytes was measured using flow
cytometry. Consistent with our previous observation
(Fig. 1b), the percentage of monocytes was increased in
PAS patients (Fig. 2a, P = 0.0086). Furthermore, the
mRNA levels of IL-6, IL-1β and VEGF-C from PBMCs
were increased in PAS patients than those of healthy
subjects (Fig. 2b, left panel, P = 0.0317; middle panel, P =
0.0138; right panel, P = 0.0218). We next isolated blood
monocytes from PAS patients and healthy subjects. Con-
centrations of IL-6 and VEGF-C from supernatants of
fresh isolated monocytes or LPS-treated monocytes were
detected by ELISA. In resting stage, blood monocytes
from PAS patients enhanced concentration of IL-6 and
VEGF-C compared with those of healthy subjects, despite
that IL-6 was secreted at low concentrations (Fig. 2c left
panel, P = 0.0060; right panel, P = 0.0009). In response to
LPS (lipopolysaccharide) stimulation, blood monocytes
significantly enhanced IL-6 production. Compared to
healthy controls, LPS-stimulated monocytes from PAS
patients produced higher concentrations of IL-6 and
VEGF-C (Fig. 2c, left panel, LPS 100 ng/mL, P =
0.0030, LPS 300 ng/mL, P = 0.0135; right panel, LPS
100 ng/mL, P = 0.0063, LPS 300 ng/mL, P = 0.0037).
Together, our data suggest that the increased number
of monocytes in PAS patients produce higher levels of
VEGF-C and IL-6 or IL-1β.
Blood monocytes in PAS patients enhance adhesion
Interestingly, similar to the result of VEGF-C, we ob-
served that the protein levels of fibrinogen in severe PAS
patients were increased compared to healthy subjects
(Fig. 3a, P = 0.0466). We next prepared PBMCs from
PAS patients and healthy subjects, and assessed their ad-
hesion ability to fibrinogen. After adherent to the
fibrinogen-coated plate, monocytes were stained with
FITC-conjugated anti-CD11b. Monocytes from PAS pa-
tients displayed spreading or enlarged morphology in re-
sponse to fibrinogen stimulation (Fig. 3b, left panel).
Moreover, increased number of monocytes from PAS pa-
tients were adherent to fibrinogen compared with those
from healthy subjects (Fig. 3b, right panel, P = 0.0021).
These data suggest that increased number of monocytes
in PAS patients adhere more strongly to fibrinogen-
containing surface.
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Discussion
Emerging observations show that monocytes play im-
portant roles in the initiation, propagation, and progres-
sion of PAS [16]. This study provides direct evidence
that peripheral monocytes from PAS patients produced
higher levels of inflammatory cytokines including IL-6
and VEGF-C, which were associated with severe PAS.
Moreover, serum concentrations of fibrinogen were also
significantly elevated in severe PAS patients. Numerous
studies indicate soluble fibrinogen in the blood stream
promotes clot formation [17]; excess fibrinogen exagger-
ates inflammation and destroys the endothelium, which
promotes atherosclerosis [18]. Therefore, persistently
elevated fibrinogen levels are a major risk factor for
Fig. 1 PAS patients enhance the number of blood monocytes and serum concentrations of IL-6 and VEGF-C. a The grades of artery stenosis and
morphology of soft or hard plaque of PAS patients were analyzed with CT. b Blood was collected from 18 healthy subjects, 23 moderate PAS
patients and 20 severe PAS patients. The number of leukocytes, monocytes and lymphocytes were calculated by Blood Cell Counter. c Protein
levels of serum IL-6 and VEGF-C from 27 healthy subjects, 31 moderate PAS patients and 22 severe PAS patients were examined with ELISA
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atherosclerosis, which predict heart attacks and strokes
with exceptional accuracy. In addition, the inflammatory
factors, such as IL-6, TNF-α, significantly contribute to
the development, progression and destabilization of ath-
erosclerotic plaques [19]; production of fibrinogen might
be enhanced by inflammatory process associated with
atherosclerosis [20]. However, few reports suggest the
participation of fibrinogen and IL-6 in the develop-
ment of PAS. Our study proposes that serum fibrino-
gen, IL-6 and VEGF-C concentrations might be used
to diagnosis severe PAS. Compared with imaging tech-
niques, such as Doppler Ultrasonography, Magnetic
Fig. 2 Blood monocytes in PAS patients produce inflammatory cytokines and VEGF-C. a PBMCs were isolated from blood of 8 healthy subjects
and 9 PAS patients by density-gradient centrifugation with Ficoll (1.077), followed by staining with FITC-conjugated anti-CD11b and APC-
conjugated anti-F4/80 for flow cytometer analysis. b Relative mRNA levels IL-6, VEGF-C or IL-1β in PBMCs from healthy subjects and PAS patients
were tested with qRT-PCR. c Freshly isolated monocytes from healthy subjects and PAS patients were either untreated (n = 6) or stimulated with
different doses of LPS for 24 h (n = 10), followed by detection of IL-6 and VEGF-C concentrations from the supernatants by ELISA. Data presented
are representative of three replicated experiments
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Resonance Angiography (MRA) or Computed Tomog-
raphy Angiography (CTA), blood or serum biomarkers
are easy to be detected by simple methods. Therefore,
detecting serum fibrinogen, IL-6, VEGF-C enables less
cost for high-throughput analysis of severe PAS in
high-risk populations.
Apart from the role in inflammatory process, athero-
sclerosis plaques have been shown to contain fibrinogen
degradation products [21], which may act as chemoattrac-
tants for leukocytes. Furthermore, VEGF-C has also been
reported to mediate cell migration [10]. We observed ele-
vated number of monocytes, but not lymphocytes, in per-
ipheral blood stream, which was correlated to the severity
of PAS. Notably, peripheral monocytes from PAS patients
increased adhesion to fibrinogen-coated surface, whereas
fibrinogen binds to integrin α5β1. The receptors for
VEGF-C are VEGFR-3 and VEGFR-2, which express on
monocytes, macrophages [7, 11] as well as on lymphatic
or vascular endothelial cells [22, 23]. Previous studies have
shown that exogenous VEGF-C treatment enhances trans-
migration ability of macrophages in vitro [11] and
VEGF-C/VEGFR-3 signaling cooperates with PI3K to
guide T lymphocyte migration in vivo [10]. It might be
expected that increased VEGF-C production in severe
PAS patients might trigger VEGFR-2/3 signaling in
monocytes to enhance integrin-mediated adhesion to
vascular wall for subsequent accumulation. We and others
previously identified the intracellular signaling proteins
ADAP (Adhesion- and Degranulation-promoting Adapter
Protein, also known as FYB or SLAP-130), SKAP-HOM
Fig. 3 Blood monocytes in PAS patients enhance adhesion. a The levels of fibrinogen in blood from 18 healthy subjects, 23 moderate PAS
patients and 20 severe PAS patients were tested. b PBMCs from 3 healthy subjects and 3 PAS patients were cultured on the plate coated with
fibrinogen for 16 h. Adherent monocytes were marked with anti-CD11b-FITC and counted with Olympus BX51 microscope. Data presented are
representative of three replicated experiments
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(SKAP55 homologue, also known as SKAP-2 or
SKAP55R) for enhancing integrin-mediated immune cell
adhesion [24–32]. Since VEGF-C/VEGFR-3 signaling acti-
vates the PI3K/AKT pathway in macrophages [7], and the
ADAP/SKAP-HOM complex expresses in macrophages
that is also linked to PI3K [33], it is interesting to further
investigate whether VEGF-C/VEGFR-3 signaling cooper-
ates with the ADAP/SKAP-HOM complex to regulate in-
tegrin activation and monocytes/macrophage adhesion.
Together, these data suggest that blood monocytes might
stick and accumulate at narrowed local artery in response
to high concentrations of serum fibrinogen and VEGF-C
in PAS, then become one main source to produce inflam-
matory cytokines and exacerbate the severity of PAS.
Additional file
Additional file 1: Figure S1. Serum concentrations of glucose (A),
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